Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: Thomson Reuters Stock Report
Provider: New Constructs, LLC
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AstraZeneca PLC and Karolinska Institute to Create Integrated Translational Research Center

Thursday, 21 Mar 2013 03:03am EDT 

AstraZeneca PLC announced that the Company and Swedish medical university Karolinska Institutet announced intention to create an Integrated Translational Research Center for cardiovascular and metabolic disease and regenerative medicine located at Karolinska Institutet’s site in Stockholm, Sweden. The Center will be set up to conduct preclinical and clinical studies aimed at advancing the understanding of cardiovascular and metabolic disease pathophysiology and assessing new drug targets for AstraZeneca’s two biotech units, AstraZeneca Innovative Medicines and Early Development (iMed) and MedImmune. Building on the organizations’ longstanding collaboration, the Center will initially run for a period of five years and will be made up of between 20 and 30 scientists, including a number of AstraZeneca scientists. In addition, AstraZeneca will contribute up to USD 20 million per annum, and Karolinska Institutet will contribute knowledge and facilities. The Center is expected to be operational by mid-2013. Karolinska Institutet has a long history of scientific collaboration with AstraZeneca. In the field of cardiovascular and metabolic disease a three-year research partnership has recently been established, focusing on advancements in cardiac regenerative therapy. This work and the new Integrated Translational Research Center will also feed into a collaboration between AstraZeneca and Moderna Therapeutics, focused on the discovery and development of messenger RNA therapeutics. 

Company Quote

42.0 +0.93%
19 Sep 2014